Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | ADK | P55263 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251951 | 0.80 | GRM5 (0.50) | GRM5 | |
| SCHEMBL22531723 | 0.80 | GRM5 (0.38) | GRM5 | |
| SCHEMBL935756 | 0.78 | GRM5 (0.34) | GRM5 | |
| SCHEMBL13907283 | 0.78 | GRM5 (0.70) | GRM5ADK | |
| SCHEMBL23235334 | 0.76 | GRM5 (0.31) | GRM5 | |
| SCHEMBL1349094 | 0.76 | HSP90AA1 (0.35) | GRM5 | |
| SCHEMBL2515112 | 0.76 | GRM5 (0.34) | GRM5 | |
| SCHEMBL14299556 | 0.76 | GRM5 (0.31) | GRM5 | |
| SCHEMBL9956785 | 0.75 | GRM5 (0.50) | GRM5 | |
| SCHEMBL11384 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110183449-A | Mnk inhibitors and methods related thereto | 效应治疗股份有限公司 | 2019-08-30 | — | — | CN | disclosed |
| CN-106795162-B | Mnk inhibitors and methods related thereto | 效应治疗股份有限公司 | 2019-07-16 | — | — | CN | disclosed |
| US-9938281-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2018-04-10 | — | — | US | disclosed |
| CN-106795162-A | Mnk inhibitors and methods related thereto | 效应治疗股份有限公司 | 2017-05-31 | — | — | CN | disclosed |
| CN-104918940-B | Purine inhibitors of human phosphatidylinositol 3-kinase | 默沙东公司 | 2017-03-08 | — | — | CN | disclosed |
| US-20160207926-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2016-07-21 | — | — | US | disclosed |
| US-20160207926-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2016-07-21 | — | — | US | disclosed |
| US-20150376172-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | WOLTERING THOMAS (US) | 2015-12-31 | — | — | US | disclosed |
| EP-2948446-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| CN-104968660-A | Fluoro-[1,3]oxazines as BACE1 inhibitors | HOFFMANN LA ROCHE | 2015-10-07 | — | — | CN | disclosed |
| US-20050261331-A1 | Substituted pyrrolopyridines | ASTRAZENECA AB (SE) | 2005-11-24 | — | — | US | disclosed |
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
| US-20050239776-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
| EP-1539757-A1 | SUBSTITUTED PYRROLOPYRIDINES | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| EP-1501809-A1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1501808-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004016609-A1 | SUBSTITUTED PYRROLOPYRIDINES | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
| WO-2003091227-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003091226-A1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
| US-4719214-A | HERPES VIRUS | SOUTHERN RESEARCH INSTITUTE (US) | 1988-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376172-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | BACE1, BACE2, PSEN1 | GRM5 478/4885HDAC8 1609/4885ADK 2815/4885 |
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | TACR1, TACR2, BDKRB1 | GRM5 1713/4885HDAC8 1076/4885ADK 1578/4885 |
| US-20050261331-A1 | Substituted pyrrolopyridines | ITK, WEE1, PDPK1 | GRM5 3432/4885HDAC8 2360/4885ADK 229/4885 |
| US-20050239776-A1 | Tachykinin receptor antagonists | TACR2, TACR1, PROKR1 | GRM5 610/4885HDAC8 2097/4885ADK 1364/4885 |
| US-20160207926-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | GRM5 3472/4885HDAC8 4827/4885ADK 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.